The USPTO granted Patent US12594301B2 to Beam Therapeutics Inc. covering compositions and methods for treating liquid cancers using genetically modified immune effector cells. The patent, application No. 17762690 filed September 25, 2020, includes 12 claims spanning multiple CPC classifications related to immune cell engineering (C12N 5/0636) and therapeutic proteins (C07K 14/705). The inventors include Jason Michael Gehrke, Aaron D. Edwards, Ryan Murray, and Waseem Qasim.

Patent holders should maintain documentation of this grant for IP portfolio management. No immediate compliance actions are required as this is an IP issuance rather than a regulatory obligation. Third parties should be aware that the patented technology is now exclusively available to Beam Therapeutics for the duration of the patent term.